The results of this large randomised, phase 3 trial in lopinavir-naive, HIV-infected, treatment-experienced patients (TITAN), showed that at week 48, significantly more patients on darunavir-ritonavir than on lopinavir-ritonavir achieved a reduction of HIV RNA (genetic material marking the presence of the virus) in the blood plasma to below 400 copies per mL (77% vs 68%). Side effects were generally mild in both groups, and led to few discontinuations of treatment.

Darunavir, a protease inhibitor, has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but has not previously been assessed in patients with a broader range of treatment experience, similar to that usually encountered in a clinical setting.

In an accompanying Comment, Bernard Hirschel and Thomas Perneger (Geneva Hospital, Geneva, Switzerland) point out that it is unlikely these results will generate a large-scale switch from lopinavir to darunavir because: "Darunavir's superior efficacy would be difficult to show in drug-naïve patients, in whom pre-existing resistance to lopinavir is not the rule...[and] darunavir-ritonavir is more expensive, particularly in the USA, than lopinavir-ritonavir."


SOURCE: The Lancet

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.